Download Sample
Add to CartGlobal Infectious Disease Diagnostic Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product;
Reagents, Kits, And Consumables, and Instruments.By Type of Testing;
Laboratory Testing, and POC Testing.By Sample Type;
Blood, Serum, and Plasma, and Urine.By Disease Type;
Hepatitis, Human Immunodeficiency Virus, Chlamydia Trachomatis Genital Infection & Gonorrhea, Hospital acquired infections, Human Papillomavirus, Tuberculosis, Influenza and Others.By End-use;
Hospital/Clinical laboratories, Reference laboratories and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Infectious Disease Diagnostic Market (USD Million), 2021 - 2031
In the year 2024, the Global Infectious Disease Diagnostic Market was valued at USD 33,639.11 million. The size of this market is expected to increase to USD 54,371.43 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.1%.
The global infectious disease diagnostic market is witnessing significant growth driven by several factors, including the increasing prevalence of infectious diseases worldwide, the emergence of new pathogens, and the growing demand for rapid and accurate diagnostic solutions. Infectious diseases pose a substantial public health challenge, necessitating prompt and precise diagnosis to facilitate timely treatment and containment efforts. As a result, there is a growing emphasis on the development and adoption of advanced diagnostic technologies capable of detecting a wide range of pathogens, including bacteria, viruses, fungi, and parasites.
Technological advancements in molecular diagnostics, immunodiagnostics, and point-of-care testing have revolutionized the landscape of infectious disease diagnosis, enabling healthcare professionals to achieve faster turnaround times, improved accuracy, and enhanced sensitivity in detecting infectious agents. Molecular diagnostic techniques such as polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS) offer unparalleled specificity and sensitivity, making them indispensable tools in the diagnosis of infectious diseases. Similarly, immunodiagnostic assays, including enzyme-linked immunosorbent assays (ELISAs) and lateral flow assays, provide rapid and cost-effective solutions for detecting infectious agents and specific antibodies in patient samples.
The global infectious disease diagnostic market is characterized by a diverse range of players, including multinational corporations, small and medium-sized enterprises, and academic institutions, contributing to the proliferation of innovative diagnostic solutions. These players are actively engaged in research and development activities to introduce novel diagnostic platforms, expand their product portfolios, and address unmet needs in infectious disease diagnosis. Moreover, strategic collaborations, partnerships, and acquisitions are prevalent in the market, enabling companies to leverage complementary technologies and expertise to enhance their market presence and drive growth in the competitive landscape of the global infectious disease diagnostic market.
Global Infectious Disease Diagnostic Market Recent Developments
- July 2022: F. Hoffmann-La Roche Ltd launched a new dual antigen and antibody diagnostic test for hepatitis C. The new Elecsys HCV Duo is one the first commercially available immunoassay test that allows the simultaneous and independent determination of the hepatitis C virus strain from a single human plasma or serum sample.
- February 2022: SEEGENE received the CE-IVD mark from the EU regulatory authority for their Allplex SARS-CoV-2 rapid MDx Assay. This assay is appropriate for use in airports, schools, and other large-scale institutions since it has the capacity to produce results in less than 30 minutes.
Segment Analysis
The Global Infectious Disease Diagnostic Market has been segmented by product, type of testing, sample type, disease type, and end-use, providing a comprehensive framework for understanding its dynamics and applications. This segmentation reflects the diverse approaches and tools available to diagnose infectious diseases efficiently.
By product, the market includes instruments, reagents, and software. Instruments such as PCR machines, immunoassay analyzers, and sequencing platforms are critical for accurate diagnostics. Reagents and kits play a vital role in ensuring reliable and repeatable results, while software facilitates data analysis and reporting, improving diagnostic precision and operational efficiency.
By type of testing, the market is divided into laboratory-based and point-of-care (POC) testing. Laboratory-based testing involves comprehensive analysis in centralized facilities, ideal for detailed diagnostics like molecular and culture-based tests. In contrast, POC testing offers rapid results at or near the site of patient care, supporting early intervention, especially in remote or emergency settings.
By sample type, the market addresses various biological specimens, including blood, urine, swabs, sputum, and tissue samples. Blood remains the most commonly used sample for detecting a wide range of pathogens, while other sample types cater to specific infections or organs.
By disease type, segmentation includes bacterial, viral, fungal, and parasitic infections. Viral diagnostics, such as those for HIV, hepatitis, and influenza, represent a significant share due to their prevalence. Bacterial testing covers diseases like tuberculosis and sepsis, while fungal and parasitic diagnostics address infections like candidiasis and malaria, respectively.
By end-use, the market serves hospitals, diagnostic laboratories, academic institutions, and point-of-care settings. Hospitals and laboratories dominate the segment, leveraging advanced diagnostic tools for accurate results. Academic institutions focus on research and development, while POC settings prioritize accessibility and rapid diagnosis.
This segmentation underscores the market's role in tackling infectious diseases across diverse healthcare scenarios, emphasizing advancements in technology, ease of access, and adaptability to varying diagnostic demands.
Global Infectious Disease Diagnostic Segment Analysis
In this report, the Global Infectious Disease Diagnostic Market has been segmented by Product, Type of Testing, Sample Type, Disease Type, End-use and Geography.
Global Infectious Disease Diagnostic Market, Segmentation by Product
The Global Infectious Disease Diagnostic Market has been segmented by Product into Reagents, Kits, And Consumables, and Instruments.
Reagents, kits, and consumables constitute a significant share of the market due to their recurring demand across diagnostic workflows. Reagents, such as enzymes, primers, and antibodies, are crucial for test preparation and execution in techniques like polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and immunoassays. Diagnostic kits, often designed for specific pathogens, simplify the testing process with pre-prepared reagents and protocols, making them popular in both laboratory and point-of-care settings. Consumables like sample collection swabs, pipettes, and culture media ensure the smooth functioning of diagnostic tests and cater to the growing emphasis on hygiene and precision.
Instruments include advanced diagnostic devices such as PCR machines, immunoassay analyzers, sequencing platforms, and automated culture systems. These instruments are integral to laboratory-based diagnostics, enabling high-throughput testing, enhanced accuracy, and faster turnaround times. Recent advancements in technology, such as portable PCR devices and integrated diagnostic systems, have broadened the application of these instruments in remote and point-of-care environments, increasing their adoption.
This segmentation reflects the symbiotic relationship between reagents, kits, consumables, and instruments in the diagnostic ecosystem. While consumables and kits ensure accessibility and operational efficiency, instruments provide the technological backbone for high-precision diagnostics. Together, these components address the rising global need for reliable, scalable, and rapid infectious disease testing.
Global Infectious Disease Diagnostic Market, Segmentation by Type of Testing
The Global Infectious Disease Diagnostic Market has been segmented by Type of Testing into Laboratory Testing, and POC Testing.
Laboratory testing dominates the market with its comprehensive capabilities in providing accurate and detailed results. This testing type involves advanced diagnostic equipment, trained personnel, and centralized facilities, making it the preferred choice for complex or confirmatory tests. Laboratory testing is integral in detecting a wide array of infectious diseases, leveraging methods such as molecular diagnostics, serological assays, and microbiological culture. Despite the higher costs and longer turnaround times compared to POC testing, its reliability and precision remain unmatched, making it a cornerstone for large-scale disease management and research.
On the other hand, POC testing has gained significant traction, especially in addressing urgent diagnostic needs in remote, underserved, or resource-constrained areas. POC testing offers convenience, rapid results, and ease of use, catering to healthcare scenarios where immediate decision-making is critical. It has been pivotal in controlling infectious disease outbreaks, allowing early detection and timely intervention. With continuous technological advancements, POC testing devices have become more sophisticated, bridging the gap between accessibility and accuracy, and further complementing traditional laboratory testing.
This segmentation highlights the evolving landscape of infectious disease diagnostics, emphasizing the importance of tailored testing approaches to meet diverse global healthcare challenges.
Global Infectious Disease Diagnostic Market, Segmentation by Sample Type
The Global Infectious Disease Diagnostic Market has been segmented by Sample Type into Blood, Serum, and Plasma, and Urine.
The blood segment is the most commonly utilized sample type for infectious disease diagnostics. Blood samples enable the detection of pathogens such as bacteria, viruses, and parasites circulating in the bloodstream. They are essential for diagnostic tests like complete blood counts, blood cultures, and molecular assays like polymerase chain reaction (PCR). Blood diagnostics are often used for diseases such as sepsis, HIV, malaria, and dengue, where systemic infections demand precise and comprehensive analysis.
The serum and plasma segment is widely used for serological and immunological testing, where the focus is on detecting antibodies or antigens associated with infectious agents. These sample types are critical for diseases like hepatitis, influenza, and COVID-19, as they allow for efficient identification of immune responses and viral presence. Tests such as enzyme-linked immunosorbent assays (ELISA) and rapid antigen tests frequently rely on serum and plasma samples due to their clarity and concentration of diagnostic markers.
The urine segment has gained prominence in the diagnosis of urinary tract infections, sexually transmitted infections, and some systemic infections. Urine samples are non-invasive, making them convenient for patient collection and testing. Molecular diagnostics, antigen tests, and microbial cultures are often performed using urine samples, offering reliable results for specific pathogens like E. coli, Chlamydia, and certain viruses. The growing adoption of urine-based diagnostics reflects the demand for less invasive yet effective testing methods.
Global Infectious Disease Diagnostic Market, Segmentation by SampleType
The Global Infectious Disease Diagnostic Market has been segmented by Disease Type into Hepatitis, Human Immunodeficiency Virus, Chlamydia Trachomatis Genital Infection and Gonorrhea, Hospital acquired infections, Human Papillomavirus, Tuberculosis, Influenza and Others.
The Global Infectious Disease Diagnostic Market is segmented by disease type to provide a comprehensive understanding of the diverse range of infectious diseases and their diagnostic needs. This segmentation allows stakeholders to identify and analyze specific categories of infectious diseases, each requiring distinct diagnostic approaches and technologies. Common disease types included in this segmentation are bacterial infections, viral infections, fungal infections, and parasitic infections, among others. Each disease type presents unique challenges in terms of diagnosis, treatment, and prevention, necessitating specialized diagnostic solutions tailored to address specific pathogens and their associated clinical manifestations.
Bacterial infections constitute a significant segment within the global infectious disease diagnostic market, encompassing a wide range of bacterial pathogens such as Escherichia coli, Staphylococcus aureus, and Mycobacterium tuberculosis. Diagnostic tests for bacterial infections often involve microbial culture, molecular techniques like PCR, and immunoassays targeting bacterial antigens or antibodies. Similarly, viral infections represent another prominent segment, with diagnostic modalities including nucleic acid amplification tests (NAATs), serological assays, and antigen detection assays utilized for detecting viruses such as influenza, HIV, and hepatitis viruses. The segmentation by disease type enables stakeholders to tailor diagnostic strategies and allocate resources effectively to address the specific challenges posed by different infectious agents and their associated diseases.
Fungal infections and parasitic infections are significant segments in the global infectious disease diagnostic market, characterized by diverse pathogens and complex diagnostic requirements. Diagnostic approaches for fungal infections often involve microscopy, culture, and molecular techniques for detecting fungal pathogens such as Candida and Aspergillus species. Similarly, diagnostic tests for parasitic infections may include microscopy, serological assays, and molecular methods for identifying parasites like Plasmodium, Trypanosoma, and Schistosoma. By segmenting the market based on disease type, stakeholders can gain insights into the prevalence, diagnostic needs, and market dynamics associated with each category of infectious diseases, thereby facilitating targeted interventions and advancements in diagnostic technologies to combat infectious diseases effectively.
Global Infectious Disease Diagnostic Market, Segmentation by End-use
The Global Infectious Disease Diagnostic Market has been segmented by End-use into Hospital/Clinical laboratories, Reference laboratories and Others.
The Global Infectious Disease Diagnostic Market is segmented by end-use to provide a comprehensive overview of the various sectors and entities involved in the diagnosis and management of infectious diseases. This segmentation categorizes end-users into distinct groups, including hospitals and clinics, diagnostic laboratories, academic and research institutions, and others such as point-of-care testing (POCT) facilities and government agencies. Each end-use segment plays a crucial role in the infectious disease diagnostic ecosystem, contributing to the demand for diagnostic products and services and shaping market dynamics.
Hospitals and clinics represent a significant segment in the global infectious disease diagnostic market, as they serve as primary points of care for patients seeking diagnosis and treatment for infectious diseases. These healthcare facilities rely on a wide range of diagnostic tests and technologies to rapidly and accurately identify infectious agents, enabling timely intervention and patient management. Diagnostic laboratories, including independent clinical laboratories and reference laboratories, also play a vital role by conducting comprehensive testing for infectious diseases, supporting healthcare providers in diagnosing and monitoring patients with suspected or confirmed infections.
Academic and research institutions contribute to the global infectious disease diagnostic market through their involvement in research, development, and validation of new diagnostic technologies and methodologies. These institutions drive innovation in the field of infectious disease diagnostics, advancing the understanding of disease pathogenesis, host-pathogen interactions, and diagnostic biomarkers. Furthermore, other end-users such as POCT facilities and government agencies are instrumental in expanding access to diagnostic services, particularly in resource-limited settings and during public health emergencies. By segmenting the market based on end-use, stakeholders can gain insights into the unique requirements and preferences of different sectors, enabling them to tailor their products and services to effectively meet the needs of various end-users and drive market growth.
Global Infectious Disease Diagnostic Market, Segmentation by Geography
In this report, the Global Infectious Disease Diagnostic Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Infectious Disease Diagnostic Market Share (%), by Geographical Region, 2024
In the preceding year, the distribution of market share in the Global Infectious Disease Diagnostic Market varied across different geographical regions, reflecting diverse healthcare landscapes, disease burdens, and economic factors. North America typically commands a significant portion of the market share, owing to its robust healthcare infrastructure, high prevalence of infectious diseases, and strong investment in diagnostic technologies. The region's emphasis on early detection and containment of infectious diseases, coupled with favorable reimbursement policies and extensive research and development activities, contributes to its prominent position in the global market.
Europe also holds a considerable market share in the Global Infectious Disease Diagnostic Market, benefiting from well-established healthcare systems, stringent regulatory frameworks, and a growing focus on preventive healthcare measures. Countries in the region prioritize public health initiatives and surveillance programs aimed at controlling the spread of infectious diseases, driving demand for advanced diagnostic solutions. Additionally, collaborations between academic institutions, healthcare providers, and diagnostic companies foster innovation and the adoption of cutting-edge diagnostic technologies, further solidifying Europe's position in the global market.
The Asia Pacific region exhibits promising growth potential in the Global Infectious Disease Diagnostic Market, fueled by factors such as rising healthcare expenditure, increasing awareness about infectious diseases, and expanding access to healthcare services. Emerging economies in the region, including China, India, and Southeast Asian countries, witness a growing demand for infectious disease diagnostics due to the high burden of communicable diseases and escalating healthcare needs. Moreover, government initiatives aimed at strengthening healthcare infrastructure and enhancing disease surveillance capabilities contribute to market expansion in the Asia Pacific region, positioning it as a key growth opportunity for market players in the global infectious disease diagnostic market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Infectious Disease Diagnostic Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Prevalence of Infectious Diseases
- Emergence of New Pathogens and Disease Outbreaks
- Demand for Rapid and Accurate Diagnostic Solutions
- Technological Advancements in Diagnostic Technologies
-
Growing Awareness and Focus on Public Health- The growing awareness and focus on public health globally have significantly influenced the dynamics of the Global Infectious Disease Diagnostic Market. With an increasing recognition of the critical role that infectious disease diagnostics play in preventing and controlling outbreaks, there has been a surge in demand for advanced diagnostic solutions. Governments, public health agencies, and international organizations are increasingly investing in initiatives aimed at improving disease surveillance, early detection, and response capabilities, driving the adoption of innovative diagnostic technologies.
Heightened public awareness about the importance of infectious disease prevention and management has led to greater emphasis on proactive healthcare measures, including routine screening and testing. This cultural shift towards prioritizing public health has created a conducive environment for market growth, with stakeholders across the healthcare spectrum increasingly recognizing the value of investing in infectious disease diagnostics. As a result, there is a growing momentum towards expanding access to diagnostic services, enhancing laboratory infrastructure, and fostering collaborations between public health authorities and diagnostic companies to address global health challenges effectively.
Restraints
- Limited Access to Diagnostic Facilities in Developing Regions
- High Cost Associated with Advanced Diagnostic Technologies
- Stringent Regulatory Requirements for Diagnostic Tests
- Challenges in Differentiating Between Similar Infectious Agents
-
Risk of False Positive or False Negative Results- The risk of false positive or false negative results poses a significant challenge in the Global Infectious Disease Diagnostic Market, impacting patient care and public health efforts. False positive results can lead to unnecessary treatment, patient anxiety, and increased healthcare costs, while false negative results may delay appropriate treatment, compromise patient outcomes, and contribute to the spread of infectious diseases. These inaccuracies can arise due to various factors such as assay limitations, specimen quality, cross-reactivity with other pathogens, and genetic variability of infectious agents, underscoring the importance of stringent quality control measures and validation protocols in diagnostic testing.
Addressing the risk of false results requires ongoing efforts to improve the accuracy, reliability, and performance of diagnostic assays and technologies. Manufacturers and regulatory agencies collaborate to establish rigorous standards for test validation, quality assurance, and proficiency testing to minimize the occurrence of false results. Additionally, healthcare professionals play a crucial role in interpreting test results in the context of clinical symptoms, epidemiological data, and patient history to mitigate the impact of false results on patient care decisions. Furthermore, advancements in diagnostic technologies, such as the integration of artificial intelligence and machine learning algorithms, hold promise for enhancing accuracy and reducing the risk of false results in infectious disease diagnostics, thereby improving patient outcomes and public health outcomes.
Opportunities
- Expansion into Emerging Markets
- Development of Multiplex Diagnostic Assays
- Integration of Artificial Intelligence (AI) and Machine Learning (ML) in Diagnostic Platforms
- Point-of-Care Testing (POCT) in Resource-Limited Settings
-
Collaboration with Public Health Agencies and Research Institutions- Collaboration with public health agencies and research institutions is paramount in the Global Infectious Disease Diagnostic Market to address complex public health challenges and advance diagnostic capabilities. These partnerships facilitate knowledge exchange, data sharing, and collaborative research initiatives aimed at improving disease surveillance, outbreak detection, and response strategies. Public health agencies play a pivotal role in providing epidemiological data, outbreak alerts, and regulatory guidance, enabling diagnostic companies to develop targeted solutions that align with public health priorities and regulatory requirements.
Collaboration with research institutions fosters innovation and technology development in infectious disease diagnostics, driving the discovery of novel biomarkers, diagnostic assays, and point-of-care testing platforms. By leveraging the expertise of academic researchers and the resources of research institutions, diagnostic companies can accelerate the translation of research findings into clinically relevant diagnostic tools. Furthermore, these collaborations facilitate clinical validation studies, regulatory approvals, and market access for new diagnostic products, ultimately enhancing the effectiveness of infectious disease diagnosis and management on a global scale.
Competitive Landscape Analysis
Key players in Global Infectious Disease Diagnostic Market include,
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company (BD)
- Siemens Healthineers AG
- QIAGEN N.V.
- Hologic, Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Type of Testing
- Market Snapshot, By SampleType
- Market Snapshot, By Disease Type
- Market Snapshot, By End-use
- Market Snapshot, By Region
- Global Infectious Disease Diagnostic Market Dynamics
- Drivers, Restraints and OpportunitiesPEST Analysis
- Drivers
- Increasing Prevalence of Infectious Diseases
- Emergence of New Pathogens and Disease Outbreaks
- Demand for Rapid and Accurate Diagnostic Solutions
- Technological Advancements in Diagnostic Technologies
- Growing Awareness and Focus on Public Health
- Restraints
- Limited Access to Diagnostic Facilities in Developing Regions
- High Cost Associated with Advanced Diagnostic Technologies
- Stringent Regulatory Requirements for Diagnostic Tests
- Challenges in Differentiating Between Similar Infectious Agents
- Risk of False Positive or False Negative Results
- Opportunities
- Expansion into Emerging Markets
- Development of Multiplex Diagnostic Assays
- Integration of Artificial Intelligence (AI) and Machine Learning (ML) in Diagnostic Platforms
- Point-of-Care Testing (POCT) in Resource-Limited Settings
- Collaboration with Public Health Agencies and Research Institutions
- Drivers
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and OpportunitiesPEST Analysis
- Market Segmentation
- Global Infectious Disease Diagnostic Market, By Product, 2021 - 2031 (USD Million)
- Reagents
- Kits
- Consumables
- Instruments
- Global Infectious Disease Diagnostic Market, By Type of Testing, 2021 - 2031 (USD Million)
- Laboratory Testing
- POC Testing
- Global Infectious Disease Diagnostic Market, By Sample Type, 2021 - 2031 (USD Million)
- Blood
- Serum
- Plasma
- Urine
- Global Infectious Disease Diagnostic Market, By Disease Type, 2021 - 2031 (USD Million)
- Hepatitis
- Human Immunodeficiency Virus
- Chlamydia Trachomatis Genital Infection and Gonorrhea
- Hospital acquired infections
- Human Papillomavirus
- Tuberculosis
- Influenza
- Others
- Global Infectious Disease Diagnostic Market, By End-use, 2021 - 2031 (USD Million)
- Hospital/Clinical laboratories
- Reference laboratories
- Others
- Global Infectious Disease Diagnostic Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia/New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Infectious Disease Diagnostic Market, By Product, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company (BD)
- Siemens Healthineers AG
- QIAGEN N.V.
- Hologic, Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market